TriSalus Life Sciences (TLSI) Income from Continuing Operations (2021 - 2026)

TriSalus Life Sciences' Income from Continuing Operations history runs 6 years deep, the most recent figure standing at 1539000.0 for Q1 2026.

• On a quarterly basis, Income from Continuing Operations rose 114.83% year-over-year to 1539000.0 in Q1 2026; TTM through Mar 2026 was 27313000.0, a 0.36% change from a year earlier, with the FY2025 full-year figure at 39227000.0, down 30.56% from the prior year.
• Income from Continuing Operations improved to 1539000.0 in Q1 2026 per TLSI's latest filing, from 9753000.0 in the prior quarter.
• Across five years, Income from Continuing Operations topped out at 2836725.0 in Q1 2022 and bottomed at 35639000.0 in Q4 2023.
• The 5-year median for Income from Continuing Operations is 8288000.0 (2025), against an average of 8967708.0.
• Biggest YoY gain for Income from Continuing Operations was 958.66% in 2022; the steepest drop was 878.46% in 2022.
• Year by year, Income from Continuing Operations stood at 22542000.0 in 2022, then slumped by 58.1% to 35639000.0 in 2023, then jumped by 71.64% to 10108000.0 in 2024, then advanced by 3.51% to 9753000.0 in 2025, then soared by 115.78% to 1539000.0 in 2026.
• Per Business Quant, the three latest TLSI Income from Continuing Operations figures stand at 1539000.0 (Q1 2026), 9753000.0 (Q4 2025), and 10811000.0 (Q3 2025).